drugset / Trial / NCT05976906
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, multi-center, phase I study to evaluate the safety, tolerability, preliminary efficacy, pharmacodynamics and immunogenicity of universal chimeric natural killer receptor modified T-cells (CNK-UT) targeting NKG2D-Ligands and NCR2-Ligands with or without lymphodepletion in advanced solid tumors.
Timeline
- Start
- 2023-05-23
- Primary completion
- 2025-05
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CNK-UT | Cell therapy | 4.6e+06 cells/kg | Intravenous |
| Subject | CNK-UT | Cell therapy | 1.5e+07 cells/kg | Intravenous |
| Subject | CNK-UT | Cell therapy | 4.6e+07 cells/kg | Intravenous |